Top Ten Pharmaceutical Events In 2007
This article was originally published in PharmAsia News
The 2007 top ten multinational pharmaceutical business events in China have been shortlisted as follows: 1) Eli Lilly & Co. put $100 million in Asian risk investment funds in China; 2) Roche established a drug R&D center in China; 3) Johnson & Johnson (China) mounted a buyback of Xian-Janssen shares; 4) Wyeth injected $58.5 million to expand its drug business; 5) Alliance BMP and Guangzhou Pharmaceutical Corp. established a joint venture; 6) GlaxoSmithKline's cervical cancer vaccine Cervarix launched in Macau; 7) Bayer acquired Topsun's OTC cough and cold medicine business; 8) Novartis boosted its OTC drug business; 9) Xian-Janssen broke ties with distributor Nanjing Pharmaceutical; 10) retail price dispute between TSKF and local drugstores. (Click here for more)
You may also be interested in...
Gilead says remdesivir improved mortality and clinical recovery in COVID-19 patients, but the findings come from a retrospective analysis, not a traditional clinical trial.
Agency resuming domestic inspections with the help of a pandemic rating system to identify localities where inspections will be safest for investigators and plant workers. Another safety factor: all inspections will be pre-announced.
Poseida, Nkarta and Inventiva raised $224m, $252m and $107.7m, respectively. Also, Forbion raised €185m ($208m) of a new €250m fund and Blackstone closed the last $1.2bn of its $4.6bn fund for public and private company deals, and Ascendis led recent follow-ons with a $569.2m offering.